Welcome to Dividend.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience


Pricing
Go Premium Now
Login
Best Dividend Stocks
Ex-Dividend Dates
High Yield Stocks
Strategies
Tools
Articles
Premium
Advisors
Guaranteed Income

Johnson & Johnson logo

News

Cardinal Health To Acquire Johnson & Johnson's Cordis Business (CAH, JNJ)

Shauna O'Brien Mar 02, 2015


Before Monday’s opening bell, Cardinal Health (CAH ) announced that it has agreed to buy Johnson & Johnson’s (JNJ ) Cordis interventional medical devices business for $1.944 billion.


Cardinal Health will purchase the Cordis business from JNJ for $1.944 billion is cash. This transaction holds a value of approximately $1.594 billion with its tax benefits. Cardinal Health expects this transaction to benefit its FY2017 Non-GAAP EPS.

The deal is expected to be completed towards the end of 2015.

CAH’s CEO George Barrett commented:“The acquisition of Cordis is a significant step forward in our cardiovascular strategy. This acquisition follows a sequence of strategic moves for Cardinal Health in the areas of cardiology, wound management and orthopedics.”

Shares of JNJ were up 39 cents, or 0.38% during premarket trading Monday. The stock is down 1.97% YTD.

Shares of CAH were down 49 cents, or 0.56% during premarket trading Monday. The stock is up 8.99% YTD.


The Bottom Line


Cardinal Health (CAH ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.

Johnson & Johnson (JNJ ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Popular Articles